With a 60% Gross margin and tightly held other costs the impact on NPAT of this type of sales increase is quite large.
On my back of the ennelope analysis a sales increase in FY'25 to $16m whilst maintaining GM% should result in a break even NPAT.
Any sales surge above $4m per quarter will likely see Biome deliver its maiden NPAT.
Cheers......D
Ann: Q1 FY25 Revenue Guidance, page-12
Add BIO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
65.5¢ |
Change
0.030(4.80%) |
Mkt cap ! $143.5M | |||
| Open | High | Low | Value | Volume |
| 64.0¢ | 68.0¢ | 63.5¢ | $363.6K | 552.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4998 | 65.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 66.5¢ | 12250 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| BIO (ASX) Chart |